VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALGS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALGSAligos Therapeutics, Inc.
$1.30$8M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALGSCash Flow

Aligos Therapeutics, Inc. (ALGS) Cash Flow Statement

8Y historyFree accessUpdated daily

Free cash flow remains consistently negative, with a 2026Q1 outflow of $23.2M, reflecting a structural inability to fund operations through internal cash generation.

Income StatementBalance SheetCash FlowRatios

ALGS Cash Flow Statement

Annual statement

ALGS Cash Flow Statement

Aligos Therapeutics, Inc. (ALGS) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-68.37M-82.5M-80.74M-79M-79.39M-115.66M-74.26M-46.77M-6.05M
Operating CF Margin %--3774.15%-2046.72%-508.71%-570.86%-2653.41%---
Operating CF Growth %16.26%-2.18%-2.21%0.49%31.36%-55.75%-58.79%-673.14%-
Net Income-66.28M-24.19M-131.21M-87.68M-96.05M-128.33M-108.54M-52.26M-13.93M
Depreciation & Amortization2.03M930K2.62M3.07M3.67M3.78M3.33M2.3M1.29M
Stock-Based Compensation5.42M5.04M8.45M12.65M14.69M13.46M2.98M752K179K
Deferred Taxes00000000-110K
Other Non-Cash Items-7.73M-60.5M44.35M2.49M-159K86K11.92M-1.23M1.64M
Working Capital Changes-1.81M-3.79M-4.96M-9.53M-1.55M-4.65M16.06M3.67M4.88M
Change in Receivables27.78M00000000
Change in Inventory000000000
Change in Payables-1.44M1.41M54K-2.22M1.72M-313K-130K385K2.98M
Cash from Investing57.78M-37.83M-18.28M44.98M-26.29M3.02M32.76M6.79M-69.29M
Capital Expenditures-289K-437K-130K-19K-943K-892K-2.06M-2.79M-2.52M
CapEx % of Revenue0.86%19.99%3.3%0.12%6.78%20.46%---
Acquisitions00000-3.91M000
Investments---------
Other Investing000003.91M00-72.84M
Cash from Financing273K101.64M355K88.33M164K78.68M192.35M85.53M99.89M
Debt Issued (Net)-151K-14K-83K-96K-61K-79K-58K-43K5M
Equity Issued (Net)-100.98M101.65M438K17.44M225K78.58M195.54M84.96M94.81M
Dividends Paid000000000
Share Repurchases000000000
Other Financing101.41M0070.98M0172K-3.14M612K77K
Net Change in Cash-10.32M-18.69M-98.67M54.31M-105.52M-33.96M150.84M45.56M24.55M
Free Cash Flow-68.66M-82.94M-80.87M-79.02M-80.33M-116.55M-76.33M-49.55M-8.56M
FCF Margin %-204.07%-3794.14%-2050.01%-508.83%-577.64%-2673.87%---
FCF Growth %13.67%-2.56%-2.35%1.64%31.08%-52.7%-54.03%-478.55%-
FCF per Share-6.56-8.39-12.91-3.18-1.88-2.92-2.23-2.26-0.40
FCF Conversion (FCF/Net Income)1.04x3.41x0.62x0.90x0.83x0.90x0.68x0.89x0.43x
Interest Paid00000006K0
Taxes Paid00000001K0

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent capital dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Disconnect Masks Cash Burn

As reported in financial statements, the OCF/NI ratio has fluctuated wildly, reaching a low of -3.85 in 2024Q2, which highlights that net income is an unreliable proxy for liquidity due to the lumpy nature of milestone-based revenue recognition and significant non-cash adjustments inherent in clinical-stage biotech operations.

The extreme volatility in the conversion ratio suggests that accounting earnings are heavily influenced by non-recurring events rather than operational cash generation. Investors should monitor the persistent gap between net income and operating cash flow, as it indicates that the company's reported profitability is largely decoupled from its actual ability to fund ongoing R&D activities.

Persistent Negative Free Cash Flow

Based on the company's reported quarterly figures, free cash flow has remained consistently negative, with a 2026Q1 outflow of $23.2M, underscoring a structural inability to generate self-sustaining cash flow while the firm continues to prioritize high-cost clinical development over operational efficiency or profitability.

The trajectory of free cash flow appears to be locked in a state of chronic deficit, reflecting the heavy reliance on external capital to bridge the gap between R&D spending and milestone receipts. This trend suggests that the company's survival is entirely dependent on its ability to secure further financing rather than internal cash generation.

Working Capital Volatility Impacts Liquidity

According to recent SEC filings, working capital changes have been highly erratic, swinging from a $5.5M outflow in 2024Q1 to a $4.1M inflow in 2024Q2, which indicates that the company's cash position is sensitive to the timing of milestone payments and the management of short-term operational liabilities.

The erratic nature of these working capital swings suggests that the company lacks a stable cash conversion cycle, which is typical for firms reliant on project-based revenue. This volatility warrants further investigation into the predictability of future cash inflows, as any delay in milestone achievement could exacerbate the existing liquidity pressure.

Cumulative Earnings Fail to Converge

As evidenced by the historical data, the cumulative divergence between net income and operating cash flow remains substantial, with the company consistently reporting cash outflows that far exceed the accounting losses, suggesting that the underlying cash reality is more constrained than the headline income figures might imply.

The persistent gap between these two metrics appears to indicate that the company is consuming cash at a rate that is not fully captured by the income statement alone. This divergence suggests that investors should focus on the absolute cash burn rate as the primary indicator of financial health rather than accounting-based profitability metrics.

SBC Masks True Operational Costs

Based on reported figures, stock-based compensation has remained a consistent feature of the cash flow statement, peaking at $2.6M in 2024Q1, which suggests that the company is utilizing equity-based incentives to preserve cash while managing the high cost of specialized talent in a competitive biotech environment.

The reliance on stock-based compensation may be obscuring the true economic cost of operations by shifting the burden of talent retention away from cash reserves. This practice appears to be a necessary survival mechanism, yet it highlights the potential for significant shareholder dilution as the company attempts to manage its limited liquidity.

ALGS — Frequently Asked Questions

Quick answers to the most common questions about buying ALGS stock.

How much cash does Aligos Therapeutics, Inc. (ALGS) generate from operations?

Aligos Therapeutics, Inc. (ALGS) generated $-82.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Aligos Therapeutics, Inc.'s free cash flow?

Aligos Therapeutics, Inc. (ALGS) reported negative free cash flow of $82.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Aligos Therapeutics, Inc.'s capital expenditure (CapEx)?

Aligos Therapeutics, Inc. (ALGS) spent $0.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.